You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
BioNTech指正寻求方法增加疫苗产量
阿思达克 12-22 11:36
《彭博通讯社》报道,辉瑞(PFE.US)合作伙伴BioNTech执行长Ugur Sahin指,正寻求通过各种方法,使明年的新冠疫苗产量能够超过之前承诺的13亿剂。

他指,相信产能明年一定可以提升,但需至明年1-2月才知道具体数字。目前正在寻找其mRNA疫苗所需的更多原料、更多无尘室以及更多合作伙伴。辉瑞目前在美国有三个疫苗生产厂,在欧洲有一个。BioNTech在德国有两个生产厂。

欧洲药品管理局指辉瑞-BioNTech疫苗或可预防英国新冠病毒新变种。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account